UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Exhibit 99.2 Press Release Business net income (a non-IFRS financial measure) for the year ended December 31, 2022 is unchanged, as is the amount of the dividend proposed by the Board of Directors held on February 2, 2023. Updated IFRS figures for 2022 Financial Statements1 | | Q4 2022 | Change | Change | 2022 | Change | Change | | --- | --- | --- | --- | --- | --- | --- | | | | | at CER | | | at CER | | IFRS net sales reported | €10,725m | +7.3% | +2.6% | €42,997m | +13.9% | +7.0% | | IFRS net income repor ...

Sanofi SA (NASDAQ:SNY) Q4 2022 Results Conference Call February 3, 2023 8:00 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care and President, North America Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - EVP and CFO John Reed - EVP and Global Head, R&D Conference Call Participants Graham Parry - BofA Peter Welford - Jefferies Richard Vosser - JPMor ...

Sanofi SA (NASDAQ:SNY) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 1:30 PM ET Company Participants Paul Hudson - CEO Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Welcome to the Sanofi presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European Pharma Analyst at JPMorgan, and it's my great pleasure to introduce Paul Hudson, the CEO of Sanofi. Before I hand over to Paul, just to remind everyone, we will take Q&A after Paul's presentation in ...

Sanofi SA (NASDAQ:SNY) Q3 2022 Results Conference Call October 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care; President, North America Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - CFO John Reed - EVP & Global Head, Research & Development Roy Papatheodorou - EVP, General Counsel & Head of Legal, Ethics & Business Brendan OÂ'Call ...

Press Release Exhibit 99.2 Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma Paris and Tarrytown, N.Y. September 5, 2022. Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncont ...

Sanofi (NASDAQ:SNY) Citi’s 17th Annual BioPharma Conference September 7, 2022 2:40 PM ET Company Participants Bill Sibold - EVP, Sanofi Genzyme; President Sanofi NA, Sanofi SA Conference Call Participants Peter Verdult - Citi Peter Verdult Okay. So good afternoon, everyone. It's Peter Verdult here from the pharma team. I'm delighted to be hosting Bill Sibold. I don't think he needs an introduction, but just for completeness, Global Head of Specialty Pharma and the President of North America. Bill, great to ...

Sanofi SA (NASDAQ:SNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Jean-Baptiste de Chatillon - EVP & CFO Bill Sibold - EVP, Sanofi Genzyme and President, Sanofi North America John Reed - EVP & Global Head, Research & Development Thomas Triomphe - Head, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Conference Call Participants Wimal Kapadia - Sanford C. Bernstein Jo Walton ...

Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices sanofi Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices sonofi ● Q2 2022 Results Play to Win July 28, 2022 Driving growth with winning assets Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwar ...

Exhibit 99.1 | | TABLE OF CONTENTS | | --- | --- | | 1. | CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 2 | | | CONSOLIDATED BALANCE SHEETS – ASSETS 2 | | | CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS' EQUITY AND LIABILITIES 3 | | | 4 CONSOLIDATED INCOME STATEMENTS | | | CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 5 | | | CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY 6 | | | CONSOLIDATED STATEMENTS OF CASH FLOWS 9 | | | NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE ...